BOSTON

波士顿

,

，

April 7, 2026

2026年4月7日

/PRNewswire/ --

/PRNewswire/ --

TransCode Therapeutics, Inc. (NASDAQ:

TransCode Therapeutics, Inc. (纳斯达克:

RNAZ

RNAZ

, the 'Company')

，公司）

, a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, today announced that it has entered into an agreement with an institutional healthcare investor for financing of up to $20 million. The arrangement comprises pre-paid advances of up to $6 million and a three-year Standby Equity Purchase Agreement (SEPA) providing the Company the right to sell up to $14 million of its common stock to the investor, subject to certain conditions..

一家处于临床阶段的公司，率先利用免疫肿瘤学和RNA技术治疗高风险和晚期癌症，今天宣布已与一家机构医疗保健投资者达成协议，融资金额高达2000万美元。该协议包括高达600万美元的预付贷款以及一份为期三年的备用股权购买协议（SEPA），根据某些条件，该协议赋予公司向投资者出售价值高达1400万美元普通股的权利。

'The financing agreement provides TransCode with financial flexibility and ensures that TransCode can maintain operational momentum as we conduct our Phase 2a trial for our lead clinical program, TTX-MC138,' said Dr. Philippe P Calais, Pharm.D., Ph.D., Chairman and CEO of TransCode.  'This runway extension should enable the Company to complete the Phase 2a study and subsequently explore a strategic collaboration for the program,' said Tom Fitzgerald, CFO of TransCode..

“融资协议为TransCode提供了财务灵活性，并确保TransCode在我们进行主要临床项目TTX-MC138的二期a阶段试验时能够保持运营动力，”TransCode董事长兼首席执行官Philippe P Calais博士表示。“这次资金支持应能使公司完成二期a阶段研究，并随后探索该计划的战略合作，”TransCode首席财务官Tom Fitzgerald表示。

About TTX-MC138

关于TTX-MC138

TTX-MC138 is a first-in-class therapeutic candidate designed to inhibit microRNA-10b, or miR-10b, a microRNA widely believed to be critical to the emergence and progression of many metastatic cancers. TransCode's Phase 0 clinical trial produced evidence of delivery of a radiolabeled version of TTX-MC138 to metastatic lesions and pharmacodynamic activity, even at a microdose of the drug candidate, suggesting a broad therapeutic window for TTX-MC138.  In the Company's Phase 1a clinical trial, TTX-MC138 met its safety endpoint and was well tolerated by patients.  A Phase 2a clinical trial with TTX-MC138 is expected to begin in the second quarter 2026. .

TTX-MC138 是一种首创新药候选疗法，旨在抑制 microRNA-10b（或 miR-10b），这种微小 RNA 被广泛认为对多种转移性癌症的出现和发展至关重要。TransCode 的 0 期临床试验提供了将放射性标记版本的 TTX-MC138 递送至转移病灶并显示出药效学活性的证据，即使在药物候选物的微量剂量下亦是如此，这表明 TTX-MC138 具有广泛的治疗窗口。在公司的 1a 期临床试验中，TTX-MC138 达到了其安全性终点，并且患者对其耐受良好。预计 TTX-MC138 的 2a 期临床试验将于 2026 年第二季度开始。

About the Financing Transaction

关于融资交易

The pre-paid advance will be evidenced by convertible promissory notes priced at 95% of face value. TransCode will issue a $1 million principal amount note concurrently with the Company's Annual Report on Form 10-K for the year ended December 31, 2025, and, subject to certain closing conditions, will issue an additional $5 million principal amount note upon shareholder approval of the transaction as required by Nasdaq rules.

预付的款项将通过按面值95%定价的可转换期票来证明。TransCode 将在公司提交截至2025年12月31日年度的10-K年报时，同步发行本金金额为100万美元的期票，并且在满足某些交割条件的前提下，根据纳斯达克规则，在股东批准该交易后，再发行本金金额为500万美元的额外期票。

The advance will accrue interest at a simple annual rate of 5% and may be converted into TransCode's common stock.  .

该预付款将按每年5%的简单利率计息，并可转换为TransCode的普通股。

Upon conversion or repayment of the convertible notes, TransCode at its option may sell up to $14 million of its common stock to the investor under terms specified in the financing agreement.

在可转换票据转换或偿还时，TransCode 可以选择根据融资协议中规定的条款向投资者出售最多 1400 万美元的普通股。

The financing agreement can be found in TransCode's Form 8-K filed with the U.S Securities and Exchange Commission.

融资协议可在 TransCode 向美国证券交易委员会提交的 8-K 表格中找到。

Tungsten Advisors acted as the Sole Placement Agent.

钨顾问公司担任了唯一的配售代理。

About TransCode Therapeutics

关于TransCode Therapeutics

TransCode Therapeutics, Inc.

TransCode Therapeutics, Inc.

is a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer. The Company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors that overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode has a portfolio of other first-in-class therapeutic candidates designed to mobilize the immune system to recognize and destroy cancer cells..

是一家处于临床阶段的公司，率先利用免疫肿瘤学和RNA技术治疗高风险和晚期癌症。该公司主要的治疗候选药物TTX-MC138专注于治疗过表达microRNA-10b的转移性肿瘤，microRNA-10b是一个独特且有充分文献记载的转移生物标志物。此外，TransCode还拥有其他一系列首创的治疗候选药物，旨在调动免疫系统识别并摧毁癌细胞。

Forward-Looking Statements

前瞻性声明

This release contains 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements concerning TransCode's technology and collaborations, statements concerning the therapeutic potential of TransCode's TTX-MC138 and other therapeutic candidates, and statements concerning the expected proceeds from the financing.

本发布包含1995年《私人证券诉讼改革法案》所指的“前瞻性声明”，包括但不限于有关TransCode技术与合作的声明、有关TransCode的TTX-MC138及其他治疗候选药物的治疗潜力的声明，以及有关融资预期收益的声明。

Any forward-looking statements in this press release are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements.

本新闻稿中的任何前瞻性陈述均基于管理层对未来事件的当前预期，并受到多种风险和不确定性的制约，这些风险和不确定性可能导致实际结果与这些前瞻性陈述中所述或暗示的结果存在重大且不利的差异。

These risks and uncertainties include, but are not limited to: the risks associated with drug discovery and development; the risk that the results of clinical trials will not be consistent with TransCode's preclinical studies or expectations or with results from previous clinical trials; risks associated with the conduct of clinical trials; risks associated with TransCode's financial condition and its need to obtain additional funding to support its business activities, including TransCode's ability to continue as a going concern; risks associated with the timing and outcome of TransCode's planned regulatory submissions; risks associated with obtaining, maintaining and protecting intellectual property; risks associated with TransCode's ability to enforce its patents against infringers and defend its patent portfolio against challenges from third parties; risks of competition from other companies developing products for similar uses; risks associated with TransCode's dependence on third parties; and risks associated with geopolitical events and pandemics, including the COVID-1.

这些风险和不确定性包括但不限于：与药物发现和开发相关的风险；临床试验结果与TransCode的临床前研究、预期或以往临床试验结果不一致的风险；与临床试验实施相关的风险；与TransCode财务状况及其需要获得额外资金以支持其业务活动相关的风险，包括TransCode能否持续经营的能力；与TransCode计划的监管提交的时间和结果相关的风险；与获取、维护和保护知识产权相关的风险；与TransCode执行其专利对抗侵权者并捍卫其专利组合免受第三方挑战能力相关的风险；来自其他开发类似用途产品的公司竞争的风险；与TransCode对第三方依赖相关的风险；以及与地缘政治事件和疫情（包括新冠疫情）相关的风险。

SOURCE TransCode Therapeutics, Inc.

来源：TransCode Therapeutics, Inc.

21

21

%

%

more press release views with

更多新闻稿浏览量与

Request a Demo

请求演示